Figure 7.
Chronic treatment with AT‐403 significantly inhibited LID at day 1, however, without interfering with its overall development. ALO AIMs were scored in 6‐OHDA hemi‐lesioned rats chronically treated for 20 days with L‐DOPA (6 mg·kg−1 plus benserazide 12 mg·kg−1, s.c.) combined with vehicle or AT‐403 0.03 mg·kg−1 (s.c., n = 9 rats per group). The time course of AIMs development over the 20 day period (A) and the AIMs response separately at days 1 (B), 9 (C), 20 (D) and 21 (challenge, E) are shown. In days different from AIMs scoring, rotarod performance was evaluated (as time on rod in seconds) before and 60 min after drug administration (F). *P < 0.05, significantly different from vehicle; two‐way RM ANOVA followed by the Bonferroni test for multiple comparisons.